Mesalazine induced interstitial nephritis

Advanced and controlled drug delivery systems in clinical disease management

Advanced and controlled drug delivery systems are important for clinical disease management. In this review the most important new systems which have reached clinical application are highlighted. Microbiologically controlled drug delivery is important for gastrointestinal diseases like ulcerative colitis and distally localized Crohn's disease. In cardiology the more classic controlled release systems have improved patient compliance and decreased side effects. In the treatment of intractable pain the spinal and transdermal route is well documented. In neurology the flattened peak-through levels of antiepileptic drugs and anti Parkinson's drugs represents a more predictable kinetic profile. Tracheal delivery of corticosteroids and sympaticomimetics in asthma and Chronic Obstructive Pulmonary Disease is fully accepted in clinical practice: delivery by this route results in better efficacy and a better safety profile. In gynaecology the delivery of pulsatile hormones (LHRH) is used for pregnancy induction, while transdermal oestrogens are promising in the prevention of osteoporosis. In surgical practice the use of antibiotic impregnated bone cement and antibiotic impregnated biodegradable collagens is well established. To prevent infections intravascular catheters coated with heparin or antibiotics are used. In ophthalmology the Ocusert systems provide a controlled release of different drugs in the eye. Most spectacular is the clinical introduction of the first liposomal drugs; amfotericine B and daunorubicine. Liposomal formulations of these drugs have enhanced activity and decreased toxicity compared to conventional formulations.

Ulcerative colitis complicated by renal cell carcinoma: a series of three patients

Three patients are described in whom renal cell carcinoma was diagnosed between seven months and 14 years after the onset of ulcerative colitis. All three had required treatment with corticosteroids and azathioprine, as well as maintenance therapy with 5-aminosalicylate derivatives, for chronic active colitis. One patient had coexisting polymyalgia rheumatica; one had primary biliary cirrhosis. It is uncertain whether this association, which has not previously been described, has pathogenetic importance or has arisen simply by chance. Genetic predisposition or the effect of drug treatment, particularly immunosuppression, may be pertinent to the co-occurrence of these diseases.